Literature DB >> 8381501

The kappa-opioid receptor: evidence for the different subtypes.

M Wollemann1, S Benyhe, J Simon.   

Abstract

Classification of drugs acting on the kappa-opioid receptors seems to be difficult, since some of these ligands are also sigma agonists and/or display non-opioid actions as well. Furthermore, certain benzomorphans having kappa-agonistic character, are shown to be mu-antagonists too. Therefore the classification of the kappa-opioid receptor has to be presently restricted to two subclasses that also have physiological meaning. Dynorphin and Met-enkephalin-Arg6-Phe7 are proposed as endogenous peptide ligands for kappa-receptors. Nonpeptide agonists are benzeneacetamides interacting with the kappa1 receptor. Benzomorphans bind to both subtypes of kappa-receptors. No selective nonpeptide ligand for the kappa2 receptor exists as yet. Nor-binaltorphimine, a specific kappa-antagonist also inhibits both kappa-subtypes. Further research for kappa2 selective drugs is necessary for clear distinction between the two kappa-opioid binding sites. Molecular cloning of opioid receptors including their subtypes are expected to provide direct proof of their existence.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381501     DOI: 10.1016/0024-3205(93)90451-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  17 in total

1.  Supraspinal administration of opioids with selectivity for mu-, delta- and kappa-opioid receptors produces analgesia in amphibians.

Authors:  C W Stevens; K S Rothe
Journal:  Eur J Pharmacol       Date:  1997-07-16       Impact factor: 4.432

2.  kappa-opioid receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative effect of opioids.

Authors:  J A Gurwell; M J Duncan; K Maderspach; A Stiene-Martin; R P Elde; K F Hauser
Journal:  Brain Res       Date:  1996-10-21       Impact factor: 3.252

Review 3.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

4.  Primary structure and functional expression of a guinea pig kappa opioid (dynorphin) receptor.

Authors:  G X Xie; F Meng; A Mansour; R C Thompson; M T Hoversten; A Goldstein; S J Watson; H Akil
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

5.  Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.

Authors:  M C Ko; M D Johnson; E R Butelman; K J Willmont; H I Mosberg; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

6.  Effects of Psychotria colorata alkaloids in brain opioid system.

Authors:  T A Amador; E Elisabetsky; D O Souza
Journal:  Neurochem Res       Date:  1996-01       Impact factor: 3.996

7.  Identification, structure-activity relationships and molecular modeling of potent triamine and piperazine opioid ligands.

Authors:  Austin B Yongye; Jon R Appel; Marc A Giulianotti; Colette T Dooley; Jose L Medina-Franco; Adel Nefzi; Richard A Houghten; Karina Martínez-Mayorga
Journal:  Bioorg Med Chem       Date:  2009-06-21       Impact factor: 3.641

8.  Direct inhibition of hypothalamic proopiomelanocortin neurons by dynorphin A is mediated by the μ-opioid receptor.

Authors:  Reagan L Pennock; Shane T Hentges
Journal:  J Physiol       Date:  2014-08-01       Impact factor: 5.182

9.  Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.

Authors:  S Salvadori; M Attila; G Balboni; C Bianchi; S D Bryant; O Crescenzi; R Guerrini; D Picone; T Tancredi; P A Temussi
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

Review 10.  Opioid research in amphibians: an alternative pain model yielding insights on the evolution of opioid receptors.

Authors:  Craig W Stevens
Journal:  Brain Res Brain Res Rev       Date:  2004-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.